News

New HIV drug’s global access hangs in the balance
HIV and global health activists say the deployment of Gilead’s twice-a-year HIV prevention shot is the world’s best chance to ...
The American Journal of Managed Care1d
Lenacapavir Offers Promising Step Forward in HIV Prevention: Q&A With Onyema Ogbuagu, MBBCh, FACP, FIDSA
The approval of lenacapavir for use as pre-exposure prophylaxis is a significant step in reducing the incidence of HIV across ...
Health Affairs2d
A Perfect Storm: “Gamechanger” HIV Prevention Medicine Launches In The Midst Of Health System And Public Health Cuts
This month, lenacapavir is expected to receive FDA approval for pre-exposure prophylaxis (PrEP). It could very well be that ...
Gilead's HIV Prevention Drug Could Be Manufactured At Shocking Low Cost: Report
Lenacapavir, a twice-yearly HIV prevention shot by Gilead, could be produced for $25 a year but may sell for $25K, raising ...
HIV: As Scientists Inch Closer to a Vaccine, Cuts to Funding Could Stall Progress
The Trump administration's plan to cut funding for HIV vaccine research comes at a time when the field is making substantial ...